Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilio Francesco Giunta

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Journal of Clinical Medicine|April 30, 2021
Bone Metastases from Gastric Cancer: What We Know and How to Deal with ThemAngelica Petrillo, Emilio Francesco Giunta, Annalisa Pappalardo, et al.
European Urology Oncology|August 13, 2023
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysisCarlo Messina, Emilio Francesco Giunta, Alessio Signori, et al.
Scientific Reports|October 20, 2020
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patientsEmilio Francesco Giunta, Giusi Barra, Vincenzo De Falco, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 6, 2019
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer modelsValentina Belli, Nunzia Matrone, Stefania Napolitano, et al.
Journal of Personalized Medicine|April 3, 2021
Treatment of Cutaneous Melanoma Harboring SMO p.Gln216Arg Mutation with Imiquimod: An Old Drug with New ResultsTeresa Troiani, Stefania Napolitano, Gabriella Brancaccio, et al.
Cancers|July 9, 2022
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCREmilio Francesco Giunta, Vincenzo De Falco, Pietro Paolo Vitiello, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 29, 2024
Correlation of [<sup>68</sup>Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patientsEmilio Francesco Giunta, Paola Caroli, Emanuela Scarpi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 27, 2025
Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II studyIrene Marini, Emilio Francesco Giunta, Silvia Nicolini, et al.
ESMO Open|November 2, 2019
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literatureGiuseppe Viscardi, Nicoletta Zanaletti, Maria Giovanna Ferrara, et al.
Medicine|May 25, 2019
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variantVincenzo De Falco, Maria Iole Natalicchio, Stefania Napolitano, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Journal of Clinical Medicine|April 30, 2021
Bone Metastases from Gastric Cancer: What We Know and How to Deal with ThemAngelica Petrillo, Emilio Francesco Giunta, Annalisa Pappalardo, et al.
European Urology Oncology|August 13, 2023
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysisCarlo Messina, Emilio Francesco Giunta, Alessio Signori, et al.
Scientific Reports|October 20, 2020
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patientsEmilio Francesco Giunta, Giusi Barra, Vincenzo De Falco, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 6, 2019
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer modelsValentina Belli, Nunzia Matrone, Stefania Napolitano, et al.
Journal of Personalized Medicine|April 3, 2021
Treatment of Cutaneous Melanoma Harboring SMO p.Gln216Arg Mutation with Imiquimod: An Old Drug with New ResultsTeresa Troiani, Stefania Napolitano, Gabriella Brancaccio, et al.
Cancers|July 9, 2022
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCREmilio Francesco Giunta, Vincenzo De Falco, Pietro Paolo Vitiello, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 29, 2024
Correlation of [<sup>68</sup>Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patientsEmilio Francesco Giunta, Paola Caroli, Emanuela Scarpi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 27, 2025
Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II studyIrene Marini, Emilio Francesco Giunta, Silvia Nicolini, et al.
ESMO Open|November 2, 2019
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literatureGiuseppe Viscardi, Nicoletta Zanaletti, Maria Giovanna Ferrara, et al.
Medicine|May 25, 2019
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variantVincenzo De Falco, Maria Iole Natalicchio, Stefania Napolitano, et al.
Pageof 6